J. Goldman & CO LP Travere Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 181,174 shares of TVTX stock, worth $3.88 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
181,174Holding current value
$3.88 Million% of portfolio
0.09%Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
214Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$164 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$157 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$144 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$106 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$91.2 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.37B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...